Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.53 |
| ▸ | PDE4A | P27815 | 17/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 17/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 17/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7654256 | 1.00 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DKDM4E | |
| SCHEMBL4957740 | 1.00 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DKDM4E | |
| SCHEMBL6607854 | 0.96 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DKDM4E | |
| SCHEMBL6607847 | 0.96 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DKDM4E | |
| SCHEMBL4958570 | 0.96 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DKDM4E | |
| SCHEMBL29357646 | 0.96 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DKDM4E | |
| SCHEMBL7659290 | 0.91 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DKDM4E | |
| SCHEMBL7659295 | 0.91 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DKDM4E | |
| SCHEMBL7659299 | 0.91 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DKDM4E | |
| SCHEMBL7656780 | 0.87 | PDE4B (0.41) | PDE4BPDE4APDE4CPDE4DKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376535-B2 | PHOSPHODIESTERASE (PDE) INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-04-23 | — | — | US | disclosed |
| US-20010056117-A1 | Oxygen-containing heterocyclic compounds | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2001-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056117-A1 | Oxygen-containing heterocyclic compounds | CBR1, CBR3, MT-CO1 | PDE4B 2596/4885PDE4A 2844/4885PDE4C 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.